Company

Colin Reisner, MD, FCCP, FAAAAI
President and CEO, Pearl Therapeutics

Sarvajna Dwivedi, PhD
Co-Founder & Chief Scientific Officer, Pearl Therapeutics

Michael Golden
Senior Vice President of Regulatory Affairs and Quality, Pearl Therapeutics

Michael Riebe, PhD
Vice President of Inhalation Product Development, AstraZeneca

Colin Reisner, MD, FCCP, FAAAAI

President and CEO, Pearl Therapeutics Inc. (Pearl)

Colin Reisner is currently the President and CEO of Pearl Therapeutics, a member of the AstraZeneca (AZ) group. He also holds the title of Head of Respiratory, Global Medicines Development, AZ. Dr. Reisner joined Pearl Therapeutics in October 2007, in the capacity of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs. In that role, he was responsible for all of the Company’s clinical development activities including advancing it’s lead programme, a combination bronchodilator, through regulatory submission.

Dr. Reisner has significant experience in the development and commercialization of inhaled respiratory products. Prior to joining Pearl, he was Executive Director for Global Respiratory Development at Novartis AG (Novartis) responsible for both clinical development and shaping Novartis’ global strategy for respiratory products. Earlier at Novartis he was the Global Brand Medical Director for Xolair®, the first biologic agent approved for asthma. Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline plc. (GSK). There he played a key role in the development of market-leading inhaled respiratory products, focusing on Advair® in Chronic Obstructive Pulmonary Disorder, and on pediatric drug development. Dr. Reisner began his career in the pharmaceutical industry at Boehringer Ingelheim GmbH and worked on a wide variety of programmes including Combivent® and on the Respimat® device.

Dr. Reisner graduated from the University of the Witwatersrand Johannesburg, Medical School, South Africa. He completed his training in Internal Medicine followed by fellowship training in Allergy and Immunology at National Jewish, Denver, Colorado, US and was an assistant consulting professor of Allergy and Immunology at Yale University, Connecticut, US and also at Duke University, North Carolina, US. Dr. Reisner is a Diplomat of the American Board of Internal Medicine and the American Board of Allergy and Immunology.

Go to Top

Sarvajna Dwivedi, PhD

Co-Founder and Chief Scientific Officer, Pearl

Sarvajna Dwivedi has extensive experience in drug development at GSK, Dura Pharmaceuticals Inc. (Dura), Alkermes plc. (Alkermes), and Nektar Therapeutics (Nektar). He was involved in the development of over 40 molecules in various therapeutic classes and dosage forms from discovery to commercialization. At Nektar, he was the Director of Product Development, responsible for new product identification, design, planning, and development efforts. At Alkermes, he was the Director of Delivery Systems, responsible for the engineering and development of inhalers for multiple products. At Dura, Dr. Dwivedi led and managed formulation design and development efforts for various Spiros programmes. Earlier, at GSK, Dr. Dwivedi was involved in the development, manufacturing, and approval of Flovent® Diskhaler, Serevent® Diskus, Advair® Diskus, Relenza® Diskhaler, and Ventolin® Evohaler.

In addition to his product development experience, Dr. Dwivedi has led and conducted technical due diligence efforts for in-licensing, out-licensing and acquisition opportunities. Dr. Dwivedi holds MSc and PhD degrees in Pharmaceutical Sciences from the University of British Columbia, Canada and M.Pharm. & B.Pharm.(Hons) from Banaras Hindu University, Varanasi, India.

Go to Top

Michael Golden

Senior Vice President of Regulatory Affairs and Quality, Pearl

Michael Golden has more than 30 years of experience in the development of respiratory and pharmaceutical products. Since joining Pearl in 2007, he has lead the Regulatory Affairs and Quality Assurance departments and played a significant role in the development and approval of Bevespi [we italicise AstraZeneca products]. Prior to joining Pearl Therapeutics, he worked for Glaxo Wellcome, where, from 1988, he played significant roles in product development, and CMC regulatory affairs, and approval for eight marketed orally inhaled and nasally delivered drugs including Flovent®, Advair®, Ventolin®, and Veramyst® Nasal Spray.

Mr. Golden received his Master of Science degree in Analytical Chemistry and BS degree in Chemistry from the University of Georgia, US.

Go to Top

Michael Riebe, PhD

Vice President of Inhalation Product Development, AZ

Mike Riebe has more than 25 years of experience in developing inhaled pharmaceutical products. He has played a significant role in developing and launching six major new products in this space during his career, including Serevent, Ventolin HFA, Advair HFA and Bevespi Aerosphere. He has also served as Vice President of R&D at iCeutica, as well as holding substantial scientific and strategic roles in Merck & Co., Inc. and GSK. Most recently, Dr. Riebe was Senior Vice President of Pharmaceutical Development and Research at Pearl. Since June 2016, he has been responsible for the Inhalation Product Development group that provides end-to-end development of inhaled products at AZ, including the legacy AZ, Sofotec and Pearl organizations (members of the AstraZeneca Group). Mr. Riebe also leads the Pharmaceutical Development and Research organization at Pearl.

Dr. Riebe received his Ph.D. in Analytical Chemistry from the University of Wisconsin-Madison, Wisconsin, US and his B.A. in Chemistry from Kalamazoo College, Michigan, US.

Dr. Riebe received his Ph.D. in Analytical Chemistry from the University of Wisconsin – Madison and his B.A. in Chemistry from Kalamazoo College.

Go to Top